Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors

Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors

The main protease (Mpro) of SARS-CoV-2 is an attractive target in anti-COVID-19 therapy for its high conservation and major role in the virus life cycle. The covalent Mpro inhibitor nirmatrelvir (in combination with ritonavir, a pharmacokinetic enhancer) and the non-covalent inhibitor ensitrelvir ha...

Full description

Bibliographic Details
Main Authors: Letian Song, Shenghua Gao, Bing Ye, Mianling Yang, Yusen Cheng, Dongwei Kang, Fan Yi, Jin-Peng Sun, Luis Menéndez-Arias, Johan Neyts, Xinyong Liu, Peng Zhan
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Acta Pharmaceutica Sinica B
Subjects:
COVID-19
SARS-CoV-2
Main protease
Non-covalent inhibitors
Medicinal chemistry strategies
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383523002939

Internet

http://www.sciencedirect.com/science/article/pii/S2211383523002939

Similar Items